CA2713075A1 - Sirna cationiques, synthese et utilisation pour l'arn interference - Google Patents

Sirna cationiques, synthese et utilisation pour l'arn interference Download PDF

Info

Publication number
CA2713075A1
CA2713075A1 CA2713075A CA2713075A CA2713075A1 CA 2713075 A1 CA2713075 A1 CA 2713075A1 CA 2713075 A CA2713075 A CA 2713075A CA 2713075 A CA2713075 A CA 2713075A CA 2713075 A1 CA2713075 A1 CA 2713075A1
Authority
CA
Canada
Prior art keywords
cationic
sirna
formula
sirna according
grafted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2713075A
Other languages
English (en)
French (fr)
Inventor
Jean-Paul Behr
Mitsuharu Kotera
Nadege Pfender
Jean-Serge Remy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite de Strasbourg
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2713075A1 publication Critical patent/CA2713075A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2713075A 2008-01-30 2009-01-30 Sirna cationiques, synthese et utilisation pour l'arn interference Abandoned CA2713075A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0800492A FR2926818B1 (fr) 2008-01-30 2008-01-30 siRNA CATIONIQUES, SYNTHESE ET UTILISATION POUR L'ARN INTERFERENCE
FR08/00492 2008-01-30
PCT/IB2009/050379 WO2009095887A1 (fr) 2008-01-30 2009-01-30 siRNA CATIONIQUES, SYNTHÈSE ET UTILISATION POUR L'ARN INTERFÉRENCE

Publications (1)

Publication Number Publication Date
CA2713075A1 true CA2713075A1 (fr) 2009-08-06

Family

ID=39683957

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2713075A Abandoned CA2713075A1 (fr) 2008-01-30 2009-01-30 Sirna cationiques, synthese et utilisation pour l'arn interference

Country Status (13)

Country Link
US (1) US10927371B2 (enExample)
EP (1) EP2250267B1 (enExample)
JP (1) JP2011511776A (enExample)
KR (1) KR20100120293A (enExample)
CN (1) CN101960009A (enExample)
AU (1) AU2009208646A1 (enExample)
BR (1) BRPI0907494A2 (enExample)
CA (1) CA2713075A1 (enExample)
FR (1) FR2926818B1 (enExample)
IL (1) IL207290A0 (enExample)
NZ (1) NZ587117A (enExample)
RU (1) RU2010136047A (enExample)
WO (1) WO2009095887A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006325054B2 (en) * 2005-12-15 2013-05-02 Centre National De La Recherche Scientifique (Cnrs) Cationic oligonucleotides, automated methods for preparing same and their uses
WO2015015498A1 (en) * 2013-07-31 2015-02-05 Qbi Enterprises Ltd. Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
AU2016226418B2 (en) 2015-03-02 2022-05-26 Synthetic Genomics, Inc. Regulatory elements from labyrinthulomycetes microorganisms
US10633454B2 (en) 2016-11-01 2020-04-28 Conagen Inc. Expression of modified glycoproteins and glycopeptides
EP3535385A4 (en) * 2016-11-01 2020-06-17 Conagen Inc. EXPRESSION OF MODIFIED GLYCOPROTEINS AND GLYCOPEPTIDES
CN106498072B (zh) * 2016-11-24 2019-09-10 青岛千卓分子生物科技有限公司 一种液态产品中外源dna内标物的保护方法及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
EP1013770A1 (en) 1998-12-23 2000-06-28 Université Louis Pasteur de Strasbourg Non-viral transfection vector
DE10207177A1 (de) 2002-02-19 2003-09-04 Novosom Ag Fakultativ kationische Lipide
US20040019008A1 (en) 2002-05-28 2004-01-29 Lewis David L. Compositions and processes using siRNA, amphipathic compounds and polycations
JP2004137143A (ja) 2002-08-21 2004-05-13 Fuji Photo Film Co Ltd 有機変性層状珪酸塩及びその組成物
EP1585756B1 (en) * 2002-11-26 2010-04-21 University of Massachusetts Delivery of sirnas
EP1638919B1 (en) * 2003-06-18 2012-09-26 Biolab Ltd. Sphingolipids polyalkylamines conjugates
WO2005060697A2 (en) * 2003-12-19 2005-07-07 Chiron Corporation Cell transfecting formulations of small interfering rna, related compositions and methods of making and use
US20060073505A1 (en) * 2004-09-21 2006-04-06 Isis Pharmaceuticals, Inc. Oligomeric compounds effecting drosha-mediated cleavage
JP2008519053A (ja) * 2004-11-04 2008-06-05 アンディーノ，ラウル 小さい干渉ＲＮＡ（ｓｉＲＮＡ）のポリアミン共役体の合成及びそれによって形成された共役体
CA2587962A1 (en) * 2004-11-17 2006-06-08 University Of Maryland, Baltimore Highly branched hk peptides as effective carriers of sirna
AU2006325054B2 (en) 2005-12-15 2013-05-02 Centre National De La Recherche Scientifique (Cnrs) Cationic oligonucleotides, automated methods for preparing same and their uses
EP1844772A1 (en) 2006-04-06 2007-10-17 Polyplus-Transfection SA Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications
EP2992875A1 (en) * 2006-04-20 2016-03-09 Silence Therapeutics GmbH Lipoplex formulations for specific delivery to vascular endothelium

Also Published As

Publication number Publication date
AU2009208646A1 (en) 2009-08-06
JP2011511776A (ja) 2011-04-14
US10927371B2 (en) 2021-02-23
EP2250267B1 (fr) 2016-09-14
CN101960009A (zh) 2011-01-26
EP2250267A1 (fr) 2010-11-17
FR2926818B1 (fr) 2012-04-06
KR20100120293A (ko) 2010-11-15
WO2009095887A1 (fr) 2009-08-06
IL207290A0 (en) 2010-12-30
FR2926818A1 (fr) 2009-07-31
NZ587117A (en) 2012-09-28
BRPI0907494A2 (pt) 2019-09-24
RU2010136047A (ru) 2012-03-10
US20110118331A1 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
Grijalvo et al. Covalent strategies for targeting messenger and non-coding RNAs: an updated review on siRNA, miRNA and antimiR conjugates
RU2571218C2 (ru) Конъюгат мирнк и способ его получения
Zhang et al. Cationic lipids and polymers mediated vectors for delivery of siRNA
Putnam et al. Polyhistidine–PEG: DNA nanocomposites for gene delivery
CA2717778C (fr) Polymere derive de la polyethylenimine lineaire pour le transfert de gene
CN117858948A (zh) 新的治疗剂递送部分及其用途
CN108026527A (zh) 确定的多偶联寡核苷酸
CA2708354C (en) Means for delivery of nucleic acids active for gene silencing using synthetic polymers
KR20100106314A (ko) Ｒｎａ 간섭 효과가 높은 지질 수식 2중쇄 ｒｎａ
EP2250267B1 (fr) siRNA CATIONIQUES, SYNTHÈSE ET UTILISATION POUR L'ARN INTERFÉRENCE
US8058256B2 (en) Polymeric carrier for delivery of small interfering RNA
CA2719963A1 (en) Double-stranded lipid-modified rna having high rna interference effect
Paris et al. Conjugating phosphospermines to siRNAs for improved stability in serum, intracellular delivery and RNAi-Mediated gene silencing
EP4323517A2 (en) Compositions containing nucleic acid nanoparticles and processes related to alteration of their physicochemical characteristics
US20070293657A1 (en) Complexes and methods of forming complexes of ribonucleic acids and peptides
FR2941152A1 (fr) Vecteurs comprenant une macromolecule anionique et un lipide cationique pour l'administration de petits acides nucleiques.
HK1153227A (en) Cationic sirnas, synthesis and use for interfering rna
WO2025122871A9 (en) Multi-armed dendrimeric oligonucleotide nanoarchitectures to target the cyclic gmp-amp (cgas)/cyclic gmp-amp receptor stimulator of interferon genes (sting) pathway
Parsons Advancement of Interpolyelectrolyte Complexes for the Delivery of Genetic Material
Bujak et al. Small interfering RNAs: heralding a new era in gene therapy
WO2005007850A1 (ja) 細胞にｒｎａを導入する方法
WO2013103693A1 (en) Nicked polynucleotide complexes for multivalent rna interference

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20150130